Assignee
ERASCA INC
US·3 granted patents·20 pending applications·1 citations·filing 2021–2024
Top patents by PatentIndex Score
23 records- 0181US12162893B2Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2021·Granted Dec 10, 2024·1 cites·4 claims
- 0270US11845761B2Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2022·Granted Dec 19, 2023·0 cites·30 claims
- 0364US12545686B2Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitorsERASCA INC·Filed 2024·Granted Feb 10, 2026·0 cites·13 claims
- 0460US2023107642A1Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2021·Application pending·0 cites
- 0558US2024293558A1Kras inhibitor conjugatesERASCA INC·Filed 2022·Application pending·0 cites
- 0658US2025313577A1Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2023·Application pending·0 cites
- 0758US2025144094A1Thiophene ulk1/2 inhibitors and their use thereofERASCA INC·Filed 2022·Application pending·0 cites
- 0855US2024285625A1Erk1/2 and kras g12c inhibitors combination therapyERASCA INC·Filed 2022·Application pending·0 cites
- 0955US2024383921A1Amide and urea-containing tricyclic kras inhibitorsERASCA INC·Filed 2022·Application pending·0 cites
- 1055US2025043012A1Antibodies against egfr and their usesERASCA INC·Filed 2023·Application pending·0 cites
- 1154US2023203063A1Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2022·Application pending·0 cites
- 1252US2024207269A1Uses of heterocyclic inhibitors of erk1/2ERASCA INC·Filed 2022·Application pending·0 cites
- 1352US2024383988A1Antibodies against egfr and their usesERASCA INC·Filed 2022·Application pending·0 cites
- 1451US2024307392A1Erk1/2 and egfr inhibitors combination therapyERASCA INC·Filed 2022·Application pending·0 cites
- 1551US2024285624A1Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapyERASCA INC·Filed 2022·Application pending·0 cites
- 1651US2024299388A1Erk1/2 and shp2 inhibitors combination therapyERASCA INC·Filed 2022·Application pending·0 cites
- 1749US2024415843A1Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitorsERASCA INC·Filed 2022·Application pending·0 cites
- 1846US2021292330A1Pyrrolidine-fused heterocyclesERASCA INC·Filed 2021·Application pending·0 cites
- 1944US2025120978A1Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapyERASCA INC·Filed 2022·Application pending·0 cites
- 2043US2024293422A1Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancerERASCA INC·Filed 2022·Application pending·0 cites
- 2140US2025195533A1Combination therapies for the treatment of cancerERASCA INC·Filed 2021·Application pending·0 cites
- 2240US2024050441A1Combination therapies for the treatment of cancerERASCA INC·Filed 2021·Application pending·0 cites
- 2339US2024058352A1Combination therapies for the treatment of cancerERASCA INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →